Dipyridamole bioavailability in subjects with reduced gastric acidity
about
Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy.Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.Electrophysiology-Based Assays to Detect Subtype-Selective Modulation of Human Nicotinic Acetylcholine ReceptorsAntiplatelet agents and proton pump inhibitors - personalizing treatment.The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.Combination antiplatelet agents for secondary prevention of ischemic stroke.Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.Targeting adenosine receptors in the development of cardiovascular therapeutics.Consequences of gastrointestinal surgery on drug absorption.Measurement of drug concentration in the stomach after intragastric administration of drug solution to healthy volunteers: analysis of intragastric fluid dynamics and drug absorption.Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.Effect of diallyl trisulfide on the pharmacokinetics of dipyridamole in rats.
P2860
Q35009459-8E65544F-62A1-426E-A6C6-5C37FC7D223FQ35565914-03998DD4-A808-4D5E-B649-96DA0DCF7CB0Q35755917-C6A6F96A-78C4-4BF9-9C77-B5C5F6002502Q36098807-9B26F711-E7D1-40B3-975B-8E72257A40DAQ36441481-E74D84CA-3E91-413A-B2A8-9463AE83B91DQ36908331-7223C402-E698-4F64-ABDA-99D03F260280Q37281572-3EFEDF77-7A4F-41F9-A489-900EA40B241DQ37872648-0E8051B2-6F47-43A2-9117-AE8B6BAC6D82Q37990558-CDDB5187-65E8-4B22-BB0B-18A7CF4381B2Q38120133-90CC1ABF-EF52-4604-93F5-3568B6266853Q44258149-7C6BCCBC-6E79-4B1A-A9D3-E4B624FBF4DCQ51257153-E69A35F5-27C5-44CA-96C8-A6902A237DD9Q52731522-EC3F3395-070B-4F01-8B12-6E83541C22B4
P2860
Dipyridamole bioavailability in subjects with reduced gastric acidity
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dipyridamole bioavailability in subjects with reduced gastric acidity
@ast
Dipyridamole bioavailability in subjects with reduced gastric acidity
@en
Dipyridamole bioavailability in subjects with reduced gastric acidity
@nl
type
label
Dipyridamole bioavailability in subjects with reduced gastric acidity
@ast
Dipyridamole bioavailability in subjects with reduced gastric acidity
@en
Dipyridamole bioavailability in subjects with reduced gastric acidity
@nl
prefLabel
Dipyridamole bioavailability in subjects with reduced gastric acidity
@ast
Dipyridamole bioavailability in subjects with reduced gastric acidity
@en
Dipyridamole bioavailability in subjects with reduced gastric acidity
@nl
P2093
P2860
P3181
P356
P1476
Dipyridamole bioavailability in subjects with reduced gastric acidity
@en
P2093
Cam P VanderMaelen
Hartmut Derendorf
Rolf-Stefan Brickl
Tom R MacGregor
Wolfgang Eisert
P2860
P304
P3181
P356
10.1177/0091270005276738
P407
P577
2005-07-01T00:00:00Z